Key points from article :
Safety administering bone marrow stromal stem cells to patients with Type 2 diabetes.
The cells were autologous, or taken from the patients own bodies.
30 adult patients with one to 25 years of Type 2 diabetes histories were recruited for the study.
Each received two infusions of the cells into an artery that supplies blood to the pancreas.
Researchers monitored the patients for 48 hours and re-examined them at 3 months interval for an year.
No significant problems were detected in the patients health, as a result of the treatment.
They appeared to benefit equally from both infusion methods.
Liem Nguyen, the institute's research director said that
"Our patients tolerated the procedure well and showed short-term reductions ..."
More than half of the patients were able to lower the doses of their diabetes medicines.
Research by Vinmec Healthcare System published in Stem Cells Translational Medicine.
